Biotech Business - January 26, 2026
Leqembi Iqlik supplemental BLA granted Priority Review by FDA
BioArctic’s partner Eisai has announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the US Food and Drug Administration (FDA).
CDMO - January 23, 2026
Northern Sweden: Diamyd Medical deepens manufacturing collaboration
Diamyd Medical is taking the next step in a long-term manufacturing collaboration with APL and, in parallel, is initiating a strategic collaboration with NorthX Biologics to further develop and scale the manufacturing of retogatein (rhGAD65) ahead of commercialization.
Collaboration - January 22, 2026
Novo Nordisk enters new phase of partnership with Aspect Biosystems
The two companies are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.
Agreement - January 21, 2026
Sigrid Therapeutics enters collaboration to commercialize SiPore
The company has entered into an exclusive global licensing and research collaboration with a multinational consumer health company to expand the SiPore technology platform into consumer oral health through a partner-led approach.
Biotech Business - January 20, 2026
Affibody carries out fully guaranteed rights issue
The Board of Directors of the company has resolved to carry out a fully guaranteed rights issue of SEK 307 million.
Global report - January 14, 2026
AstraZeneca acquires Modella AI
AstraZeneca is acquiring its AI partner Modella AI to own and deploy multimodal AI foundation models in‑house across discovery and development.
